The World Health Organization has officially named Vietnam as the fifth country in the Western Pacific region to meet requirements to produce vaccines for the global market, with reports in April suggesting the government expects to have a 6-in-1 vaccine ready for the market next year.
U.K.-based Companies and Markets, an aggregator of market research, has released a report predicting the global market for animal vaccines will hit $7.2 billion by 2020.
A move by Takeda Pharmaceutical to consolidate its Vaccine Business Unit into hubs should allow sharper focus on a complex set of vaccine programs covering norovirus, dengue and seasonal influenza in an increasingly competitive global horse race.
India's Zydus Cadila Healthcare has around 10 vaccines under development and plans to launch them in India next year, the company said in an earnings call that followed full-year results, entering a busy market in the country that sees a mix of major foreign and domestic players.
Only about 30% of teens receive a second meningitis shot at age 16 as recommended by the CDC, and for vaccine maker Sanofi Pasteur, that's a problem. But the French drugmaker is hoping it can change that, and to do so, it's teaming up with a teen idol.
China's National Health and Family Planning Commission has issued new regulations ordering transparency in the handling of vaccines and vaccination equipment to ensure their safety.
The Drug Controller General of India, G.N. Singh, told India Today the government has been working with Hilleman on a proposal to research and develop formulations of oral rotavirus vaccines that are thermostable across a variety of temperatures and environmental conditions.
Vietnam has become the 39th nation cleared for global exports of the vaccines it makes, joining an increasingly crowded field of local champions to multinational heavyweights. The World Health Organization gave that clearance recently for a country that expects to be a leading producer within the next 20 to 30 years.
This past season's flu vaccines posted one of the worst efficacy rates in recent memory. That's partly because the viral strains they contained weren't the ones that ended up circulating. But on top of that, GlaxoSmithKline has uncovered some other effectiveness problems of its own--and now it's recalling a quadrivalent jab in a move that affects 1.7 million doses.
As it beefs up its vaccines business, Pfizer's looking to bolster revenue from the top-selling Prevenar family of shots. But on that front, it's come up against a roadblock in China--and so it's shutting down its vaccines marketing there.